Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD

 editorial team spoke in an interview with Benjamin Locksin, MD, regarding new tyrosine kinase 2 (TYK2) inhibitors for psoriasis.

Lockshin, an assistant professor of dermatology at Georgetown University, had co-presented a session at the conference titled ‘Seminar-in-Depth: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’ The team asked him about his session and some of the most notable highlights for clinicians to be aware of on this topic.

“TYK2 inhibitors have really changed the landscape in terms of our management of patients with psoriasis,” Lockshin noted. “For moderate to severe patients that are looking for an oral option, I think TYK2 inhibitors like deucravacitinib have allowed us to have meaningful response rates for psoriasis vulgaris, as well as utilization and tough-to-treat areas like the scalp, palms, and soles.”

In one example, Lockshin highlighted the efficacy of the TYK2 inhibitor deucravacitinib, describing the medication as ideal for moderate disease.

“...I think that patients who are either younger or older may be good candidates [for deucravacitinib],” Locksin explained. “The younger patient that's in their late teens, or early twenties, with moderate to severe psoriasis may have no issue incorporating just one other pill into their routine. Many patients don't want the hassle of having an injection, especially if you're living in a group house or in a college dorm. You may not want that injectable in your fridge. Just having that pill keeps your disease state personal, so other people don't need to know what's going on.”

Lockshin also described the emerging TYK2 inhibitors for psoriasis as a complement to other available psoriasis treatment options, including biologics.

“I do think that biologic efficacy outperforms oral agents in general,” Lockshin said. “But certainly individual responses, especially in that moderate category, are very good in achieving high levels of clearance and its certainly possible with a medication like deucravacitinib.”

Lockshin described the present day as an exciting time in the psoriasis management space, both as a patient and as a clinician treating patients with psoriasis. He also touched on icotrokinra as a potentially strong option for patients.

“These newer oral agents, including two new TYK2 inhibitors that can potentially add to increase levels of efficacy, as well as an IL-23 peptide like [icotrokinra], will allow patients more oral options to achieve higher levels of success,” Lockshin said. “I am specifically excited about the introduction of icotrokinra, as I think we'll be able to lean in on the safety from IL-23 biologics, but also have a once-daily option for managing patients.”

For any additional information on this subject, view the full video posted above. To learn more about news in dermatology, view our 

The quotes contained in this summary were edited for clarity.

Lockshin previously reported fees from AbbVie, Eli Lilly, Regeneron, Sanofi, Boehringer Ingelheim, Incyte, Leo Pharma, Pfizer, and UCB.

Lockshin B, Del Rosso J. Seminar-in-Depth: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis. Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Bissonnette R, Soung J, Lebwohl M, et al. Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial. Presented at DERM 2025 NP PA CME Conference; July 23-26, 2025; Las Vegas, Nevada.

Videos

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Kevin Alexander, MD | Image Credit: Stanford University School of Medicine

Acoramidis has shown its efficacy in reducing all-cause mortality (ACM) in patients with 

 with both wild-type (ATTRwt-CM) and a pathogenic variant (ATTRv-CM), which was consistent out to month 42 of the ATTRibute-CM study’s open-label extension.

American Heart Association’s Scientific Sessions 2025

 in New Orleans, Louisiana, in a series of moderated and unmoderated digital posters. The results are consistent with previously presented results from the ATTRibute-CM study in the wild-type population, as well as in the population overall.

“These data represent an important finding for patients with the V142I variant of ATTR-CM, a population that has historically had limited access to early diagnosis and treatment,” Kevin Alexander, MD, Stanford University School of Medicine, said in a statement. “These results are encouraging for individuals with variant ATTR-CM and reflect progress in advancing precision medicine and promoting equity in cardiovascular care.”

ATTRibute-CM was a phase 3, randomized, double-blind, 30-month study comparing acoramidis 712 mg and matching placebo. Patients were randomly assigned in a 2:1 ratio to either treatment delivered daily for 30 months, which would be followed by 12 months of open-label treatment. Patient stratification was based on TTR genotype, N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels, and estimated glomerular filtration rate (eGFR) levels. During the study, patients were allowed to initiate tafamidis at the discretion of the investigator as a concomitant medication, once they had completed 12 months of treatment.

A total of 632 participants were initially enrolled; 611 of these were included in a modified intent-to-treat (mITT) population. Of these, 9.7% (n = 59) exhibited ATTRv-CM at randomization; the other 552 had ATTRwt-CM. Ultimately, 39 participants were assigned to acoramidis and 20 to placebo. Efficacy outcomes of the trial included all-cause mortality, cardiovascular-related hospitalizations, serum TTR, 6-minute walk distance, and NT-pro-BNP.

Investigators saw consistent efficacy in both ATTRv-CM and ATTRwt-CM for both all-cause mortality and cardiovascular-related hospitalizations through month 30, and in all-cause mortality through month 42. By month 30, acoramidis reduced the risk of both versus placebo by 31% in ATTRwt-CM (HR, 0.69; 95% CI, 0.52-0.9; 

 = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; 

 = .01). All-cause mortality was likewise reduced through month 42 with HRs of 0.7 (95% CI, 0.5-0.98; 

 = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively.

In patients with ATTRv-CM receiving acoramidis, sTTR increased at day 28, reaching comparable levels to participants with ATTRwt-CM receiving acoramidis. This was despite a roughly 25% lower sTTR level in the ATTRv-CM population at baseline. However, an increase in NT-proBNP was observed over 30 months in the placebo arms; the increase was numerically greater among patients with ATTRv-CM than those with ATTRwt-CM.

Investigators concluded that a consistent clinical benefit was displayed across multiple endpoints, including all-cause mortality, functional status, cardiovascular health, NT-proBNP, serum TTR, and quality of life in both the ATTRwt-CM and ATTRv-CM groups. The team notes the reinforcement of acoramidis’s therapeutic benefit based on these data.

“Acoramidis may have the potential for ATTR disease primary prevention in carriers of pathogenic TTR variants,” Alexander and colleagues wrote. “This concept is currently being evaluated in the ACT-EARLY clinical trial. In addition, further studies are warranted to evaluate the efficacy of acoramidis in transthyretin-mediated polyneuropathy, based on the assumption that near-complete TTR stabilization may confer therapeutic benefits similar to those observed in ATTR-CM.”

BridgeBio. Acoramidis significantly reduces all-cause mortality in the overall attr-cm variant and v142i (v122i) populations. November 8, 2025. Accessed November 14, 2025. 

https://investor.bridgebio.com/news/news-details/2025/Acoramidis-Significantly-Reduces-All-cause-Mortality-in-the-Overall-ATTR-CM-Variant-and-V142I-V122I-Populations/default.aspx

Alexander K, Davis M, Akinboboye O, et al. Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. 

. November 08, 2025. Accessed November 14, 2025. 

Articles

Acoramidis has demonstrated efficacy in reducing all-cause mortality in patients with both wild-type and variant amyloid cardiomyopathy (ATTR-CM) through the ATTRibute-CM study and its open-label extension. The study, presented at the American Heart Association’s Scientific Sessions 2025, showed consistent results in reducing mortality and cardiovascular-related hospitalizations. Acoramidis also improved functional status, cardiovascular health, and quality of life. The study suggests potential for primary prevention in carriers of pathogenic TTR variants and highlights the need for further research in transthyretin-mediated polyneuropathy.

Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

ATTRibute-CM: Acoramidis Lowers Mortality in Patients With Amyloid Cardiomyopathy

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 has cleared BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) system for use as an adjunct therapy in adolescents aged 15 to 21 years with 

The news, announced on November 13, 2025, expands the use of the TMS device, which had previously been approved for patients aged 22 – 86 years in 2018.

“The FDA’s clearance of this expanded label enables access to Deep TMS for the critically important adolescent patient population, which is often underserved by traditional pharmacological options to manage major depressive disorder,” said Colleen Hanlon, VP of Medical Affairs, BrainsWay Ltd, in a statement. “The 510(k) clearance was supported by our submission of one of the largest real-world adolescent neuromodulation datasets ever presented to the US FDA, which demonstrated compelling efficacy and safety in reducing depressive symptoms, as well as substantial improvements in comorbid anxiety.”

The TMS device offers noninvasive magnetic stimulation through a cushioned helmet to induce electrical currents in localized regions of the prefrontal cortex. The treatment requires daily sessions of 20 minutes throughout 4 – 6 weeks.

 Although the treatment may take a few weeks to start improving MDD symptoms, patients may notice subtle improvements sooner, such as being more alert, having more energy during the day, or having more patience.

In the study supporting the expanded use of the TMS device, patients aged 15 to 21 years with MDD received 36 sessions of either high-frequency (18 Hz) Deep TMS or intermittent theta-burst stimulation.

 The analysis demonstrated an average improvement of 12.1 points on the self-administered Patient Health Questionnaire-9 (PHQ-9) rating scale and a 66.1% response rate (improvement from baseline of ≥50%). Investigators also observed improvements in anxiety, reflected by changes in self-administered Generalized Anxiety Disorder (GAD-7) scale scores.

Overall, the treatment was well-tolerated with similar adverse events as observed in adult studies.

Previous studies with participants aged 22 – 86 years found no known systemic effects; the most common adverse events included headaches and local discomfort, often mild and temporary. Other adverse events included muscle twitching and jaw pain.

Along with MDD, the FDA has cleared BrainsWay’s Deep TMS system for the treatment of obsessive-compulsive disorder (OCD), anxious depression, and smoking cessation.

BrainsWay Deep TMS Gains FDA Clearance for Adolescent Depression. MPR. Published November 13, 2025. Accessed November 14, 2025. 

https://www.empr.com/news/brainsway-deep-tms-gains-fda-clearance-for-adolescent-depression/

Payesko J. BrainsWay’s Next Generation Stimulator For Treatment of MDD Cleared by FDA. 

. Published May 9, 2018. Accessed November 14, 2025. 

https://www.hcplive.com/view/brainsways-next-generation-stimulator-for-treatment-of-mdd-cleared-by-fda 

Sehic A. What is a BrainsWay Deep TMS Device? BrainsWay. Published December 15, 2022.

 https://www.brainsway.com/knowledge-center/what-is-a-brainsway-deep-tms-device/

The FDA has approved BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) system for adolescents aged 15 to 21 with major depressive disorder (MDD), expanding its previous approval for adults aged 22 to 86. This noninvasive treatment involves daily sessions over 4-6 weeks, showing significant efficacy in reducing depressive symptoms and improving anxiety. The study supporting this approval demonstrated a 66.1% response rate and was well-tolerated with mild adverse events. Deep TMS is also approved for obsessive-compulsive disorder, anxious depression, and smoking cessation.

FDA clears BrainsWay's Deep TMS for adolescents aged 15-21 years with major depressive disorder (MDD), expanding its use.

FDA News

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Panelists discuss how future oral therapy research should focus on studying younger pediatric populations, implementing early intervention strategies, and investigating whether newer oral agents can reduce the incidence of psoriatic arthritis development.

Expert Perspectives on Oral Treatment Research Needs for the Future

Patients would benefit from expanded research into oral psoriasis treatments for younger age groups, as children under 12 years with psoriasis face limited treatment options despite significant psychological and developmental impacts. Early intervention becomes crucial for pediatric patients, as untreated psoriasis during childhood can affect self-esteem, classroom participation, and social development, potentially preventing children from reaching their full potential. Research extending oral treatment options to younger patients could provide life-changing benefits for families managing pediatric psoriasis.

Early treatment intervention may help patients avoid long-term complications, including the potential development of psoriatic arthritis later in life. Research suggests that patients receiving prompt, effective treatment within 2 years of diagnosis achieve better outcomes than those who experience delayed treatment initiation. Studies indicate that early intervention with systemic therapies may reduce the incidence of psoriatic arthritis development, suggesting that new oral agents might provide similar protective benefits for patients when used early in their disease course.

Real-world studies will help patients and providers understand how oral treatments perform outside controlled clinical trial settings, providing valuable insights into long-term effectiveness, adherence patterns, and patient satisfaction. Future research should examine combination therapy approaches, optimal timing for treatment initiation, and strategies for maintaining long-term remission for patients using oral medications. These investigations will help establish best practices for integrating advanced oral therapies into comprehensive psoriasis care, ensuring patients receive maximum benefit from these innovative treatment options.

Video Series

Peers Perspectives

Moshiur Rahman Khasru, MBBS, MSc, PhD candidate at University of Manchester, and Musculoskeletal Medicine and Interventional Physiatry Division, Bangladesh Medcial University, Dhaka, Bangladesh

Adipose-Derived MSCs Show Promise as Nonsurgical Option for Knee OA, With Moshiur Rahman Khasru, MBBS, MSc

Two-dose adipose-derived mesenchymal stem cells (AdMSC) therapy significantly outperformed hyaluronic acid (HA) and single-dose AdMSC in improving pain, function, and cartilage structure in people with knee osteoarthritis (KOA).

American College of Rheumatology (ACR) Convergence 2025

, held October 24–29 in Chicago, Illinois, by Moshiur Rahman Khasru, MBBS, MSc, PhD candidate at University of Manchester, and Musculoskeletal Medicine and Interventional Physiatry Division, Bangladesh Medcial University, Dhaka, Bangladesh.

For people with KOA who are either ineligible or unwilling to undergo surgery, there is a need for safe, nonsurgical interventions that address not only symptoms but also cartilage degeneration itself. HA remains a widely used intra-articular treatment, but benefits are modest and short-lived, typically lasting just 3–6 months. Evidence directly comparing HA with regenerative approaches has also been lacking.

Khasru and colleagues conducted a phase IIb, evaluator-blinded trial in Bangladesh to compare intermediate molecular-weight HA with autologous AdMSCs—including both single- and 2-dose regimens—to determine relative efficacy, safety, and potential dose responsiveness. Seventy-three patients with refractory primary KOA were randomized and assessed at baseline and at 6 months using VAS pain, KOOS function, ultrasound-measured femoral cartilage thickness, and MRI-evaluated MOAKS cartilage defects.

Interim 6-month results showed that 2-dose AdMSC therapy produced significantly greater clinical and structural improvements than HA, including a 3.2-point reduction in VAS pain versus 1.3 points with HA and a 21.24-point improvement in KOOS function compared with 11.31 points in the HA group (

 <.001). Structural endpoints showed similar dose-dependent advantages: femoral cartilage thickness increased by 0.25 ± 0.18 mm and MRI-assessed cartilage defects (MOAKS) improved by 9.13% in the two-dose AdMSC arm, whereas the HA group demonstrated structural decline with cartilage thinning of –0.06 ± 0.14 mm and a 0.75% worsening in cartilage defects.

The single-dose AdMSC group also outperformed HA, showing superior pain reduction, functional gains, and favorable cartilage changes, though to a lesser extent than the 2-dose regimen. Across all arms, no baseline predictors of response were identified, and all treatments were well-tolerated, supporting the safety of both HA and autologous AdMSCs in this phase IIb trial.

"Most [patients] are doing the reasonably well with conservative treatment, but a significant proportion of the patients, they do not respond to the conservative treatment, which includes painkillers, lifestyle modification, including weight reduction, therapeutic exercise, physical therapies... even though they show modification, still, then they do not respond well and live with pain and functional limitations," Khasru said in an interview with 

where he sat down with his coinvestigator Mahbuba Shirin, MD, Professor, Mahbuba Shirin Department of Radiology and Imaging, Bangladesh Medical University, Dhaka, Bangladesh.

Khasru had no relevant disclosures to report.

Khasru MR, Islam MT, Jubery AGMZN, et al.Adipose-Tissue Derived Mesenchymal Stem Cells vs Hyaluronic Acid in Refractory Knee Osteoarthritis in a low-resource setting: A Phase IIb RCT. Presented at: ACR Convergence 2025; October 24-29; Chicago, Illinois. Abstract #LB07

Khasru discussed the potential of adMSCs to improve outcomes in knee osteoarthritis.

Osteoarthritis

On the HCPLive osteoarthritis page, resources on the topics of medical news and expert insight into OA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on degenerative joint disease, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

ALA Spokesperson and professor at Baylor College of Medicine.

Polverino stresses the need for prospective analysis to validate CC16 and mucus plugs as viable biomarkers for COPD status.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Eosinophils, CC16, and the Role of COPD Biomarkers, with Francesca Polverino, MD, PhD

Bakhos explains the ideal patient population and strategies inherent to LVRS success.

Optimizing Lung Volume Reduction Surgery, with Charles Bakhos, MD, MBA, MS

Friedberg explains how an emphasis on physical fitness prior to and after surgery can significantly better long-term outcomes.

Lung Cancer

Surgery

The HCPLive surgery page is a resource for medical news and expert insights on invasive medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for surgery, and more.

Managing Perioperative, Postoperative Lung Cancer, with Joseph Friedberg, MD

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Podcasts

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Don't Miss a Beat: POLY-HF & the Potential of Polypills in HF, With Ambarish Pandey, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD

James Tumlin, MD, is the president of NephroNet, director of research at Georgia Nephrology, and a professor of medicine in nephrology at Emory University School of Medicine.

Tumlin discussed improvements in UPCR and Gd-IgA1 seen with povetacicept.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Povetacicept Data Validate APRIL/BAFF Inhibition in IgAN and pMN, With James Tumlin, MD

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD

Ayah Matar, MD, is a postdoctoral researcher at Mayo Clinic.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.


Latest News

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD

ATTRibute-CM: Acoramidis Lowers Mortality in Patients With Amyloid Cardiomyopathy

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Expert Perspectives on Oral Treatment Research Needs for the Future

Adipose-Derived MSCs Show Promise as Nonsurgical Option for Knee OA, With Moshiur Rahman Khasru, MBBS, MSc